The Post talked to three people taking semaglutide, plus one weight loss doctor, to find out what’s motivating them to stay mum. Jennifer*, a 50-something from New Jersey, has lost 40 lbs.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as ...

Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with ...

Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes. In the intervening years, a lucrative industry of telehealth ...

What Happens If I Use Expired Semaglutide? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the type 2 diabetes and weight loss medication sold under the brand ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...